Video

Dr. Parker on the Role of Radiotherapy in Newly Diagnosed Prostate Cancer

Chris Parker, MD, consultant clinical oncologist, The Royal Marsden NHS Foundation Trust, discusses the role of radiotherapy in newly diagnosed prostate cancer.

Chris Parker, MD, consultant clinical oncologist, The Royal Marsden NHS Foundation Trust, discusses the role of radiotherapy in newly diagnosed prostate cancer.

Results from the STAMPEDE trial presented at the 2018 ESMO Congress showed that men with low metastatic disease burden who received radiotherapy plus standard of care had a 32% improvement in overall survival (OS) compared with men who received standard of care treatment alone.

In the prespecified subgroup analysis, radiotherapy to the prostate improved OS by 32% in the 819 men with a low burden of metastatic disease (HR 0.68, 95% CI 0.52-0.90). The absolute improvement in OS in this group at 3 years was 81%. Radiotherapy conferred no survival benefit in the men with a high metastatic disease burden, though.

Related Videos
Paolo Caimi, MD
Jennifer Scalici, MD
Steven H. Lin, MD, PhD
Anna Weiss, MD, associate professor, Department of Surgery, Oncology, associate professor, Cancer Center, University of Rochester Medicine
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Hematology/Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine
Victor Moreno, MD, PhD
Louis Crain Garrot, MD
Benjamin P. Levy, MD, with Kristie Kahl and Andrew Svonavec
Bradley C. Carthon, MD, PhD
Fred Saad, CQ, MD, FRCS, FCAHS, director, Prostate Cancer Research, Montreal Cancer Institute, Centre Hospitalier de l’Université de Montréal; full professor, Department of Surgery, Université de Montréal; uro-oncologist, Urology Department, University of Montreal Health Center